OBJECTIVE: To systematically evaluate the efficacy and safety of Anluo Huaxian pills combined with entecavir in improving liver fibrosis and imaging indicators in patients with hepatitis B-related liver cirrhosis.METHODS: CNKI

Wanfang Data

VIP

CBM

PubMed

Embase and the Cochrane Library were retrieved to collect the randomized controlled trial of Anluo Huaxian pills combined with entecavir in the treatment of hepatitis B-related liver cirrhosis. The retrieval time was from the establishment of the database to Nov. 6 th

2021. The methodological quality of the included literature was evaluated by using the Cochrane bias risk assessment tool

and data were analyzed by using RevMan 5. 3 software. RESULTS: Totally 26 literature were enrolled

including 2 663 patients. Meta-analysis results showed that Anluo Huaxian pills combined with entecavir in the treatment of hepatitis B-related liver cirrhosis can reduce the hyaluronic acid（ HA） level during decorpesated period（ MD =-59. 97

95% CI =-68. 15--51. 79）

laminin（ LN） level（ MD =-62. 20

95%CI =-78. 15--46. 25）

type Ⅳ collagen（ Ⅳ-C） level（ MD =-48. 02

95% CI =-54. 19--41. 85） and HA level during decompensated period（ MD =-145. 04

95% CI =-154. 92--135. 17）

LN level（ MD =-86. 38

95% CI =-105. 77--66. 98）

type Ⅲ procollagen level（ MD =-131. 05

95% CI =-142. 53--119. 56）

Ⅳ-C level（ MD =-108. 22

95%CI =-122. 49--93. 95）

reduce the inner diameter of portal vein（ MD =-0. 07

95%CI =-0. 14--0. 01）

reduce the thickness of spleen（ MD =-3. 28

95%CI =-4. 10--2. 46）

increase the improvement rate of portal vein diameter（ RR = 1. 55

95% CI = 1. 37-1. 75）

and increase the improvement rate of splenic vein diameter（ RR = 1. 77

95% CI = 1. 52-2. 06） and other aspects were significantly better than entecavir monotherapy

and the differences were statistically significant（ P < 0. 05）. CONCLUSIONS: Anluo Huaxian pills combined with entecavir in the treatment of hepatitis B-related liver cirrhosis can more effectively reduce the level of liver fibrosis and improve the imaging indicators such as portal vein internal diameter and spleen thickness in patients.